Invited by Tenthpin, one of Europe's fastest growing specialist life sciences system integrators, to open its annual company gathering in Antalya, Turkey.
Featured inBloombergThe Wall Street JournalThe Telegraph
The host's verdict
Futurist and storyteller, dropped jaws with his vision of a future that's already knocking on our doors.
Tenthpin
Tenthpin, one of Europe's fastest-growing specialist life sciences system integrators, invited Matthew to give the opening keynote at its annual company get-together, held at the Concorde Hotel in Antalya, Turkey. With all 400 of the company's employees in the room, he opened the day with a look at what the next fifteen or so years hold for animal health, healthcare and life sciences.
The picture was truly science-fiction-like. Biotech and pharma companies believe that by 2028 we should reach ‘Escape Velocity’, the point when the sum of medical breakthroughs extends human life by more than a year for every year that passes. Given the breakthroughs we are seeing today, which will in time mature commercially and win regulatory approval, eventually in real time, Matthew argued that this vision is not far fetched.
"In time all of these breakthroughs will make 60 the new 30 and could see us all live healthy, vibrant lives that extend well beyond the age of 100."Matthew Griffin, Antalya, February 2025
Some breakthroughs benefit animals and humans alike, such as gene therapies and smart devices that monitor the health of populations. Others apply mainly to people: 3D and 4D printed organs and tissues, anti-ageing and rejuvenation technologies, hybrid human immune systems, in vivo gene editing, cancer vaccines and predictive medicines, rapid gene sequencing and personalised medicines.
Taken together, Matthew showed, these advances could make 60 the new 30 and let us all live healthy, vibrant lives well beyond the age of 100.
311 Intelligence
What this means for your leadership team
Plan for much longer lives.
If breakthroughs make 60 the new 30, workforces, pensions, insurance and products all change. Organisations should test their plans against customers who live well beyond 100.
Expect care to move before illness.
Predictive medicines and population health monitoring shift care towards prevention. Providers and insurers that move early can reshape their models.
Prepare for regulation to speed up.
Matthew expects breakthroughs to win approval faster over time. Life sciences firms need product pipelines ready for that pace.
Three questions for your next leadership meeting
How would our business change if our customers routinely lived beyond 100?
Which of our services could move from treating illness to predicting it?
Are our pipelines ready for faster regulatory approval?
The trends and technologies behind this session
From the 311 Starburst, the 311 Strategic Intelligence Unit’s map of the technologies and trends shaping the next 50 years.
What does the future of life sciences mean for organisations?
Longer, healthier lives and predictive care change demand for healthcare, insurance, pensions and consumer products. Life sciences firms face faster pipelines and new competitors.
How does Predictive Healthcare relate to this keynote?
Matthew included predictive medicines among the key breakthroughs. The 311 Starburst tracks Predictive Healthcare as a trend expected to be mainstream around 2029.
When does 311 expect in vivo gene therapy to be in wide use?
The 311 Starburst expects in vivo gene therapy, which fixes faulty genes inside the body, to reach wide use around 2049.
How can 311 brief our leadership team on this?
Through a private executive briefing or leadership workshop, tailored to your sector, in person first.
Bring this to your leadership teamA private executive briefing or leadership workshop, tailored to your sector. In person first, anywhere in the world.
Analysis by the 311 Strategic Intelligence Unit, from Matthew Griffin’s session and 311 data.
If Matthew gave this session today
Hundreds of emerging technologies, and what they mean.
The Future of Exponential Technology Codex explores hundreds of emerging technologies and their implications for global culture, industry and society, the context for the breakthroughs now reshaping healthcare and life sciences.
